Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 Sep;76(3):999–1006. doi: 10.1172/JCI112101

Effect of prostacyclin on vascular capacity in the dog.

T G Fulghum, J P DiMarco, E W Supple, I Nash, J Gendlerman, D F Eton, J B Newell, R M Zusman, W J Powell Jr
PMCID: PMC423965  PMID: 3930573

Abstract

Since the discovery of prostacyclin (PGI2) in 1976, there has been great interest in its vascular effects and potential clinical applications. High infusion rates of PGI2 markedly depress arterial blood pressure both in animal studies and in clinical trials. This fall in pressure may result entirely from a decrease in arterial resistance. However, it is possible that the administration of PGI2 may decrease ventricular filling due to an increase in vascular capacity. To investigate whether or not PGI2 affects vascular capacity, we infused PGI2 intraarterially at both 10 and 25 micrograms/min into 15 dogs on total cardiopulmonary bypass. These infusions were associated with a 25 +/- 3 mmHg decrease in arterial pressure and an increase in vascular capacity of 155 +/- 29 ml (SE, P less than 0.005). This increase in capacity was greater (P less than 0.02) than the increase of 23 +/- 42 ml resulting from infusions of nitroglycerin into eight dogs at 2 mg/min, which produced a decrease in arterial pressure of 23 +/- 4 mmHg, which was the maximal effect that could be achieved. Neither bilateral cervical vagotomy nor beta adrenergic blockade with propranolol significantly diminished the increase in vascular capacity associated with infusions of PGI2. The results from studies in four eviscerated dogs indicated that PGI2 acts on both splanchnic and extrasplanchnic capacity vasculature. To compare the direct effects of PGI2 with those of nitroglycerin and nitroprusside on venous tone, we used an isolated canine spleen preparation. Infusions of PGI2 (100 mcg/min) increased spleen weight in this preparation by 9.0 +/- 2.4% (n = 10, P less than 0.001); this increase was significantly greater than increases of 3.6 +/- 2.2% (P less than 0.001) and 3.5 +/- 2.3% (P less than 0.001) caused by high dose infusions of nitroglycerin (1 mg/min) and nitroprusside (400 micrograms/min), respectively. Thus, PGI2 substantially increases vascular capacity by a mechanism that appears to involve a direct action on vascular smooth muscle. Furthermore, these results suggest that PGI2 might be useful in clinical conditions in which an increase in vascular capacity is indicated.

Full text

PDF
999

Images in this article

1000Image
on p.1000
1001Image
on p.1001
1003Image
on p.1003

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ABOUD F. M., ECKSTEIN J. W., ZIMMERMAN B. G. VENOUS AND ARTERIAL RESPONSES TO STIMULATION OF BETA ADRENERGIC RECEPTORS. Am J Physiol. 1965 Aug;209:383–389. doi: 10.1152/ajplegacy.1965.209.2.383. [DOI] [PubMed] [Google Scholar]
  2. Araki H., Lefer A. M. Role of prostacyclin in the preservation of ischemic myocardial tissue in the perfused cat heart. Circ Res. 1980 Nov;47(5):757–763. doi: 10.1161/01.res.47.5.757. [DOI] [PubMed] [Google Scholar]
  3. Aren C., Feddersen K., Rådegran K. Effects of prostacyclin infusion on platelet activation and postoperative blood loss in coronary bypass. Ann Thorac Surg. 1983 Jul;36(1):49–54. doi: 10.1016/s0003-4975(10)60648-0. [DOI] [PubMed] [Google Scholar]
  4. Belch J. J., McKay A., McArdle B., Leiberman P., Pollock J. G., Lowe G. D., Forbes C. D., Prentice C. R. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial. Lancet. 1983 Feb 12;1(8320):315–317. doi: 10.1016/s0140-6736(83)91625-2. [DOI] [PubMed] [Google Scholar]
  5. Bennett B. M., Moffat J. A., Armstrong P. W., Marks G. S. Investigation of the role of prostaglandins in nitroglycerin-induced relaxation of isolated rabbit blood vessels. Can J Physiol Pharmacol. 1983 Jun;61(6):554–560. doi: 10.1139/y83-085. [DOI] [PubMed] [Google Scholar]
  6. Bergman G., Daly K., Atkinson L., Rothman M., Richardson P. J., Jackson G., Jewitt D. E. Prostacyclin: haemodynamic and metabolic effects in patients with coronary artery disease. Lancet. 1981 Mar 14;1(8220 Pt 1):569–572. doi: 10.1016/s0140-6736(81)92028-6. [DOI] [PubMed] [Google Scholar]
  7. Blair I. A., MacDermot J. The binding of [3H]-prostacyclin to membranes of a neuronal somatic hybrid. Br J Pharmacol. 1981 Mar;72(3):435–441. doi: 10.1111/j.1476-5381.1981.tb10994.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Borchert J., Franke J., Lichey J. Reduction of acute pulmonary hypertension by prostacyclin. Cor Vasa. 1980;22(4):281–287. [PubMed] [Google Scholar]
  9. Boullin D. J., Bunting S., Blaso W. P., Hunt T. M., Moncada S. Responses of human and baboon arteries to prostaglandin endoperoxides and biologically generated and synthetic prostacyclin: their relevance to cerebral arterial spasm in man. Br J Clin Pharmacol. 1979 Feb;7(2):139–147. doi: 10.1111/j.1365-2125.1979.tb00914.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bunting S., Gryglewski R., Moncada S., Vane J. R. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins. 1976 Dec;12(6):897–913. doi: 10.1016/0090-6980(76)90125-8. [DOI] [PubMed] [Google Scholar]
  11. Carlson L. A., Olsson A. G. Intravenous prostaglandin E1 in severe peripheral vascular disease. Lancet. 1976 Oct 9;2(7989):810–810. doi: 10.1016/s0140-6736(76)90653-x. [DOI] [PubMed] [Google Scholar]
  12. Chapple D. J., Dusting G. J., Hughes R., Vane J. R. Some direct and reflex cardiovascular actions of prostacyclin (PGI2) and prostaglandin E2 in anaesthetized dogs. Br J Pharmacol. 1980 Mar;68(3):437–447. doi: 10.1111/j.1476-5381.1980.tb14557.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cohn J. N., Franciosa J. A. Vasodilator therapy of cardiac failure: (first of two parts). N Engl J Med. 1977 Jul 7;297(1):27–31. doi: 10.1056/NEJM197707072970105. [DOI] [PubMed] [Google Scholar]
  14. Dembinska-Kiec A., Gryglewska T., Zmuda A., Gryglewski R. J. The generation of prostacyclin by arteries and by the coronary vascular bed is reduced in experimental atherosclerosis in rabbits. Prostaglandins. 1977;14(6):1025–1034. doi: 10.1016/0090-6980(77)90282-9. [DOI] [PubMed] [Google Scholar]
  15. Dusting G. J., Chapple D. J., Hughes R., Moncada S., Vane J. R. Prostacyclin (PGI2) induces coronary vasodilatation in anaesthetised dogs. Cardiovasc Res. 1978 Dec;12(12):720–730. [PubMed] [Google Scholar]
  16. Dusting G. J., Moncada S., Vane J. R. Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins. 1977 Jan;13(1):3–15. doi: 10.1016/0090-6980(77)90037-5. [DOI] [PubMed] [Google Scholar]
  17. Einzig S., Sotomora R., Rao G. H., Gerrard J. M., Foker J. E., White J. G. Effect of low dose prostacyclin infusion on blood flow in acutely ischemic canine myocardium. Prostaglandins Med. 1980 Sep;5(3):209–219. [PubMed] [Google Scholar]
  18. Faichney A., Davidson K. G., Wheatley D. J., Davidson J. F., Walker I. D. Prostacyclin in cardiopulmonary bypass operations. J Thorac Cardiovasc Surg. 1982 Oct;84(4):601–608. [PubMed] [Google Scholar]
  19. Lefer A. M., Ogletree M. L., Smith J. B., Silver M. J., Nicolaou K. C., Barnette W. E., Gasic G. P. Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science. 1978 Apr 7;200(4337):52–54. doi: 10.1126/science.345441. [DOI] [PubMed] [Google Scholar]
  20. Levin R. I., Jaffe E. A., Weksler B. B., Tack-Goldman K. Nitroglycerin stimulates synthesis of prostacyclin by cultured human endothelial cells. J Clin Invest. 1981 Mar;67(3):762–769. doi: 10.1172/JCI110093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Levy J. V. Contractile responses to prostacyclin (PGI2) of isolated human saphenous and rat venous tissue. Prostaglandins. 1978 Jul;16(1):93–97. doi: 10.1016/0090-6980(78)90205-8. [DOI] [PubMed] [Google Scholar]
  22. Miller R. R., Vismara L. A., Williams D. O., Amsterdam E. A., Mason D. T. Pharmacological mechanisms for left ventricular unloading in clinical congestive heart failure. Differential effects of nitroprusside, phentolamine, and nitroglycerin on cardiac function and peripheral circulation. Circ Res. 1976 Jul;39(1):127–133. doi: 10.1161/01.res.39.1.127. [DOI] [PubMed] [Google Scholar]
  23. Moncada S., Vane J. R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1978 Sep;30(3):293–331. [PubMed] [Google Scholar]
  24. Needleman P., Johnson E. M., Jr Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther. 1973 Mar;184(3):709–715. [PubMed] [Google Scholar]
  25. Opdyke D. F., Ward C. J. Spleen as an experimental model for the study of vascular capacitance. Am J Physiol. 1973 Dec;225(6):1416–1420. doi: 10.1152/ajplegacy.1973.225.6.1416. [DOI] [PubMed] [Google Scholar]
  26. Pitt B., Shea M. J., Romson J. L., Lucchesi B. R. Prostaglandins and prostaglandin inhibitors in ischemic heart disease. Ann Intern Med. 1983 Jul;99(1):83–92. doi: 10.7326/0003-4819-99-1-83. [DOI] [PubMed] [Google Scholar]
  27. Rubin L. J., Groves B. M., Reeves J. T., Frosolono M., Handel F., Cato A. E. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982 Aug;66(2):334–338. doi: 10.1161/01.cir.66.2.334. [DOI] [PubMed] [Google Scholar]
  28. Rutlen D. L., Supple E. N., Powell W. J., Jr beta-Adrenergic regulation of total systemic intravascular volume in the dog. Circ Res. 1981 Jan;48(1):112–120. doi: 10.1161/01.res.48.1.112. [DOI] [PubMed] [Google Scholar]
  29. Rådegran K., Arén C., Teger-Nilsson A. C. Prostacyclin infusion during extracorporeal circulation foe coronary bypass. J Thorac Cardiovasc Surg. 1982 Feb;83(2):205–211. [PubMed] [Google Scholar]
  30. Schrör K., Grodzinska L., Darius H. Stimulation of coronary vascular prostacyclin and inhibition of human platelet thromboxane A2 after low-dose nitroglycerin. Thromb Res. 1981 Jul 1;23(1-2):59–67. doi: 10.1016/0049-3848(81)90238-3. [DOI] [PubMed] [Google Scholar]
  31. Simon B., Kather H., Kommerell B. Prostacyclin: a potent activator of human colonic adenylate cyclase activity. Z Gastroenterol. 1978 Dec;16(12):748–751. [PubMed] [Google Scholar]
  32. Supple E. W., Powell W. J., Jr Effect of acetylcholine on vascular capacity in the dog. J Clin Invest. 1981 Jul;68(1):64–74. doi: 10.1172/JCI110255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Szczeklik A., Gryglewski R. J., Nizankowski R., Skawiński S., Głuszko P., Korbut R. Prostacyclin therapy in peripheral arterial disease. Thromb Res. 1980 Jul 1;19(1-2):191–199. doi: 10.1016/0049-3848(80)90418-1. [DOI] [PubMed] [Google Scholar]
  34. Szczeklik J., Szczeklik A., Nizankowski R. Prostacyclin for pulmonary hypertension. Lancet. 1980 Nov 15;2(8203):1076–1076. doi: 10.1016/s0140-6736(80)92291-6. [DOI] [PubMed] [Google Scholar]
  35. Watkins W. D., Peterson M. B., Crone R. K., Shannon D. C., Levine L. Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension. Lancet. 1980 May 17;1(8177):1083–1083. doi: 10.1016/s0140-6736(80)91522-6. [DOI] [PubMed] [Google Scholar]
  36. Webb-Peploe M. M., Shepherd J. T. Beta-receptor mechanisms in the superficial limb veins of the dog. J Clin Invest. 1969 Jul;48(7):1328–1335. doi: 10.1172/JCI106099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Yui Y., Nakajima H., Kawai C., Murakami T. Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol. 1982 Aug;50(2):320–324. doi: 10.1016/0002-9149(82)90183-7. [DOI] [PubMed] [Google Scholar]
  38. Zelis R., Mason D. T. Isosorbide dinitrate. Effect on the vasodilator response to nitroglycerin. JAMA. 1975 Oct 13;234(2):166–170. doi: 10.1001/jama.234.2.166. [DOI] [PubMed] [Google Scholar]
  39. Zusman R. M., Crow J. W., Cato A. E., Tolkoff-Rubin N. Effects of prostacyclin infusion in uremic patients: hematologic and hemodynamic responses. Clin Pharmacol Ther. 1981 Aug;30(2):251–257. doi: 10.1038/clpt.1981.156. [DOI] [PubMed] [Google Scholar]
  40. Zusman R. M., Rubin R. H., Cato A. E., Cocchetto D. M., Crow J. W., Tolkoff-Rubin N. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med. 1981 Apr 16;304(16):934–939. doi: 10.1056/NEJM198104163041603. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES